Mercury Laboratories Performance Comparison

Loading chart data...

Stock Range

Today's Range

Low: ₹840.00 High: ₹860.00
on August 18, 2025

52 Week Range

Low: ₹736.00 High: ₹1,190.00
on March 4, 2025
on October 9, 2024

All-Time High: ₹1,303.00 on January 8, 2024

Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights

Key Statistics

Market Cap i INR998.5M
EPS i 26.21
P/E Ratio (TTM) i 31.75
Forward P/E i N/A
P/B Ratio i 1.86
PEG Ratio i N/A
Div. Yield i 0.82%
ROE i 5.87%
Beta i 0.626
Debt to Equity i 10.18

Financial Highlights

Profitability

Gross Margin i 61.02%
Operating Margin i 8.34%
Profit Margin i 4.93%

Returns and Earnings

Return on Assets (TTM) i 4.24%
Return on Equity (TTM) i 5.87%
EBITDA i INR80.9M
Net Income (TTM) i INR37.7M

Growth

Revenue (TTM) i
Revenue Per Share (TTM) i INR638.00
Quarterly Revenue Growth (YoY) i 8.70%
Quarterly Earnings Growth (YoY) i 183.30%

Dividend Information

Last 12-Month Dividend i ₹7.00
Current Dividend Yield i 0.82%
3-Year Average Dividend Yield i 0.43%
3-Year Average Annual Dividend i ₹4.67
3-Year Total Dividends i ₹14.00
Ex-Dividend Date i August 6, 2025

Peer Performance Comparison

Performance comparison table showing returns for peer companies over various time periods
CompanyMarket Cap1W1M3M6MYTD1Y3Y5Y
Mercury Laboratories MERCURYLAB 998.46M Small-cap-5.06%-3.51%-1.71%-2.00%-6.52%-11.21%78.94%85.83%
Sun Pharmaceutical SUNPHARMA 3.94T Large-cap2.69%-2.45%-3.91%-3.48%-13.15%-5.82%82.10%208.33%
Divi's Laboratories DIVISLAB 1.63T Large-cap0.02%-9.53%-1.34%4.94%0.98%32.34%65.91%88.85%
Sun Pharma Advanced SPARC 45.51B Small-cap-3.92%-13.01%-6.93%-0.76%-30.12%-34.25%-41.92%-22.97%
Aarti Drugs AARTIDRUGS 44.42B Small-cap-3.86%1.23%5.23%18.26%6.84%-2.04%8.97%-37.88%
Sequent Scientific SEQUENT 43.92B Small-cap0.45%-5.27%0.82%19.96%-4.81%22.66%59.79%34.23%

Ownership & Short Interest

Insider Ownership i 86.13%
Institutional Ownership i 0.00%
Shares Short i N/A
Short Ratio i N/A
Short % of Shares Outstanding i N/A
Average 10-Day Volume i 92
Average 90-Day Volume i 174

Mercury Laboratories Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Mercury Laboratories would have performed over time.

INR
If not specified, the latest available data will be used

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

In the last 52 weeks, Mercury Laboratories reached a high of ₹1,190.00 (on October 9, 2024) and a low of ₹736.00 (on March 4, 2025).
Curious about Mercury Laboratories's size and valuation? Its market capitalization stands at 998.46M. When it comes to valuation, the P/E ratio (trailing twelve months) is 31.75, and the forward P/E (looking ahead) is N/A.
Yes, Mercury Laboratories is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.82%, and the company has paid an average of ₹4.67 per share annually over the past 3 years.

When looking at Mercury Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

CompanyMkt CapSectorIndustry1Y Return3Y Return
Sun Pharmaceutical
SUNPHARMA
3.94THealthcareDrug Manufacturers - Specialty & Generic-5.82%82.10%
Divi's Laboratories
DIVISLAB
1.63THealthcareDrug Manufacturers - Specialty & Generic32.34%65.91%
Sun Pharma Advanced
SPARC
45.51BHealthcareDrug Manufacturers - Specialty & Generic-34.25%-41.92%
Aarti Drugs
AARTIDRUGS
44.42BHealthcareDrug Manufacturers - Specialty & Generic-2.04%8.97%
Sequent Scientific
SEQUENT
43.92BHealthcareDrug Manufacturers - Specialty & Generic22.66%59.79%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

To get a sense of Mercury Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 5.87%, the Debt to Equity ratio from the most recent quarter is 10.18, and its Gross Profit Margin stands at 61.02%.
Looking at Mercury Laboratories's growth, its revenue over the trailing twelve months (TTM) was INR766M. Compared to the same quarter last year (YoY), quarterly revenue grew by 8.70%, and quarterly earnings saw a YoY growth of 183.30%.
Wondering who owns Mercury Laboratories stock? Company insiders (like executives and directors) hold about 86.13% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.